(Q30908652)

27 June 2017

1 reference

title

Infection risk in patients on multiple sclerosis therapeutics (English)

1 reference

27 June 2017

1 reference

Eric M Williamson

1

1 reference

27 June 2017

Joseph R Berger

series ordinal

2

1 reference

27 June 2017

publication date

1 March 2015

1 reference

27 June 2017

1 reference

27 June 2017

volume

29

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

page(s)

229-244

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Influence of Peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Inflammation, demyelination, and degeneration - recent insights from MS pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Innate immune responses in central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The systemic response to brain injury and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Clinical viral infections and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Prospective study on the relationship between infections and multiple sclerosis exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Infections and the risk of relapse in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The risk of relapses in multiple sclerosis during systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Central inflammation versus peripheral regulation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Multiple sclerosis: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Natalizumab for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

New and emerging disease modifying therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

New oral drugs for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Emerging oral drugs for relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Oral treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The impact of systemic infection on the progression of neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy and newer biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Use of glucocorticoids and risk of infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Infections associated with steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Pharmacology of glucocorticoids in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Multiple sclerosis treatment and infectious issues: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Mitoxantrone: benefits and risks in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

An integrated safety profile analysis of belatacept in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Fingolimod and multiple sclerosis: four cautionary tales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Herpes encephalitis during natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Natalizumab and HSV meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Immunological risk factors for infection after immunosuppressive and biologic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The structure and function of the S1P1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Varicella vaccination after fingolimod: A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Cladribine for multiple sclerosis: review and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Laquinimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Daclizumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Daclizumab for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40263-015-0226-2

21 January 2018

12 December 2020

Infectious risks of immunomodulating therapies in rheumatology

1 reference

12 December 2020

PML in a patient treated with fumaric acid

1 reference

12 December 2020

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

1 reference

12 December 2020

Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.

1 reference

12 December 2020

1 reference

12 December 2020

Insight into the mechanism of laquinimod action

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.

1 reference

12 December 2020

Neurological complications of biologic therapy in psoriasis: a review.

1 reference

12 December 2020

Primary varicella zoster infection associated with fingolimod treatment

1 reference

12 December 2020

The pathogenesis of progressive multifocal leukoencephalopathy

1 reference

12 December 2020

FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia

1 reference

12 December 2020

Immunotherapy of multiple sclerosis: the state of the art.

1 reference

12 December 2020

Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system

1 reference

12 December 2020

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

1 reference

12 December 2020

Report of Three Cases of Herpes Zoster During Treatment with Natalizumab

1 reference

12 December 2020

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

1 reference

12 December 2020

Fingolimod treatment for multiple sclerosis patients What do we do with varicella?

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP)

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

1 reference

12 December 2020

Leflunomide-associated infections in rheumatoid arthritis

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

1 reference

12 December 2020

10.1007/S40263-015-0226-2

Identifiers

DOI

1 reference

27 June 2017

1 reference